Pyxis Oncology posts updated Phase 1 results for micvotabart pelidotin

Pyxis Oncology reported updated Phase 1 results for micvotabart pelidotin in recurrent or metastatic head and neck cancer, with data dated October 14, 2026. The study showed a 39% confirmed response rate among 33 evaluable patients, median progression-free survival of 6.7 months, median response duration of 9.2 months, and a 94% disease control rate. Pyxis plans to begin the global HeadlinerSM Phase 3 trial in mid-2027 and expects more mature overall-survival results during the first half of 2027.

The results provide additional clinical data before Pyxis moves the program into Phase 3. The planned trial and forthcoming survival update are the next milestones for investors assessing the drug candidate.

  • 1The October 14, 2026 data showed a 39% confirmed objective response rate among 33 evaluable patients treated at 5.4 mg/kg once every three weeks.
  • 2The study reported median progression-free survival of 6.7 months, median response duration of 9.2 months, and a 94% disease control rate.
  • 3Six patients developed Grade 3 peripheral neuropathy, and five of those cases improved to Grade 1 or better.
  • 4Pyxis plans to start the global HeadlinerSM Phase 3 trial in mid-2027.
  • 5Pyxis expects to provide more mature overall-survival results during the first half of 2027.

Sources